Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04213807 · ClinicalTrials.gov registry record · Phase 2
A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
A Phase 2 study, sponsored by Anthos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04213807 is a Phase 2 study that has completed, run by Anthos Therapeutics. The registered enrollment target is 28 participants.
The verdict
NCT04213807, a Phase 2 study, has completed, sponsored by Anthos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or peripheral embolism.
Interventions
- OTHER Placebo
- BIOLOGICAL MAA868 Cohort 1
- BIOLOGICAL MAA868 Cohort 2
- BIOLOGICAL MAA868 Cohort 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2021-03-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04213807
The ClinicalTrials.gov registry entry for NCT04213807 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthos Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04213807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04213807 about?
NCT04213807 is a clinical study titled "A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation". This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or f...
What is the current status of trial NCT04213807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-12-11. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT04213807?
The interventions under investigation include: Placebo (OTHER), MAA868 Cohort 1 (BIOLOGICAL), MAA868 Cohort 2 (BIOLOGICAL), MAA868 Cohort 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04213807?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.